Tag Archives: media

White blood cells play unexpected role in clearing out dead liver cells – EurekAlert

A type of white blood cell usually associated with immune responses to foreign particles may have another role in clearing out liver cells that have undergone apoptosis where cells are programmed to die in a controlled manner.

The study, published today as a Reviewed Preprint in eLife, provides what the editors describe as solid evidence that neutrophils destroy liver cells going through apoptosis by burrowing into them a process the authors have called perforocytosis. The findings also suggest that a lack of neutrophils may be a cause of human autoimmune liver disease (AIL), with potential implications for new therapeutic strategies against the disease.

Billions of apoptotic cells are removed daily in adults by a group of immune cells called phagocytes. Neutrophils represent around 5070% of the total white blood cell population in humans and are a type of phagocyte. However, unlike other phagocytes, they were widely assumed to be excluded from apoptotic cells, as they promote inflammation which could damage nearby healthy cells and tissues. The current findings now challenge that assumption.

Although apoptotic cells are well characterised, they are not often found within human samples, possibly because they are removed so efficiently by phagocytes, says co-lead author Luyang Cao, Associate Investigator in the Department of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, China. This means that the specific phagocytes responsible for the removal of apoptotic cells remain unknown, and we do not know if they are specific to different tissues in the body.

To identify the phagocytes responsible for removing apoptotic cells in the liver, the team obtained cells from the liver tissue of patients with tumours caused by hepatocellular carcinoma or hepatic hemangioma. They used two different staining techniques to confirm which cells in the sample were apoptotic.

In a total of 281 apoptotic liver cells from the livers of 32 patients, the team noticed that each cell was engorged by the presence of up to 22 neutrophils. It has previously been suggested that a type of phagocyte called Kupffer cells were responsible for the clearance of apoptotic liver cells, but when the researchers searched for Kupffer cells in the samples, they found that very few were present. They therefore hypothesised that neutrophils were the primary phagocyte for the removal of dead liver cells through the process they called perforocytosis. This contrasts to the usual process of engulfing apoptotic cells that most other phagocytes use.

To confirm the mechanism by which neutrophils remove apoptotic liver cells, the team sought to visualise the process in mouse livers using intravital microscopy a live imaging technique that allows biological processes to be viewed in real time within living organisms. They labelled liver cells with a protein called Annexin V and neutrophils with an anti-Ly6G antibody. Consistent with their findings in human samples, the team observed that neutrophils burrowed into and cleared dead liver cells in the mice. The process was fast and rigorous, with the dead cells completely digested in four to seven minutes.

Our discovery of neutrophils burrowing into and clearing out apoptotic liver cells helps to solve some of the mysteries surrounding the apoptotic clearance process, says co-corresponding author Hexige Saiyin, Assistant Professor in the State Key Laboratory of Genetic Engineering, School of Life Sciences,Fudan University, China.

Next, the team sought to investigate whether reducing the neutrophil population in mice impacts the clearance of apoptotic liver cells. In a sample of cells from the livers of neutrophil-depleted mice, the percentage of apoptotic cells was significantly higher than in normal mice 0.92% and 0.2%, respectively suggesting that neutrophil depletion impairs the clearance of apoptotic cells. They also noticed the presence of other phagocytes in the neutrophil-depleted mice, implying a compensatory role of other phagocytes in the absence of neutrophils.

The defective clearance of apoptotic cells is often linked with autoimmune diseases, such as AIL. In the neutrophil-depleted mice, the team noticed an increase in autoantibodies immune cells that mistakenly attack the bodys own healthy cells instead of foreign bodies such as viruses or bacteria. This increase was unaffected by antibiotic treatments and present only in neutrophil-depleted mice, not in mice with other phagocyte depletions. This implies that neutrophil depletion is associated with impaired apoptotic liver cell clearance and, subsequently, the generation of autoantibodies that may lead to AIL disease. The team consolidated this finding by analysing biopsy samples from human patients with AIL disease. Once again they found that, in each patient, the neutrophil-mediated clearance of apoptotic cells was impaired.

The authors say that more research is needed to better understand the process and significance of perforocytosis, as well as whether perforocytosis occurs in other organs besides livers. The next important step is how to apply this newly identified apoptotic clearance mechanism to the clinical treatment of AIL.

Since the failure to clear dead cells is linked to inflammatory and autoimmune diseases, further insights into the critical role that neutrophils play in apoptotic clearance may have important implications for the treatment of these diseases. We recently have screened and identified several compounds which markedly enhanced neutrophil perforocytosis and demonstrated great therapeutic values to cure AIL in mouse models. concludes senior author Jingsong Xu, former Principal Investigator at the Department of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University (current address: Department of Pharmacology, Center for Lung and Vascular Biology, University of Illinois, Chicago).

##

Reference

The Reviewed Preprint, An unexpected role of neutrophils in clearing apoptotic hepatocytes in vivo, is available to view at https://doi.org/10.7554/eLife.86591.1. Contents, including text, figures and data, are free to reuse under a CC BY 4.0 license.

Media contacts

Emily Packer, Media Relations Manager

eLife

e.packer@elifesciences.org

+44 (0)1223 855373

George Litchfield, Marketing and PR Assistant

eLife

g.litchfield@elifesciences.org

About eLife

eLife transforms research communication to create a future where a diverse, global community of scientists and researchers produces open and trusted results for the benefit of all. Independent, not-for-profit and supported by funders, we improve the way science is practised and shared. In support of our goal, weve launched a new publishing model that ends the accept/reject decision after peer review. Instead, papers invited for review will be published as a Reviewed Preprint that contains public peer reviews and an eLife assessment. We also continue to publish research that was accepted after peer review as part of our traditional process. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.

To read the latest Medicine research published in eLife, visit https://elifesciences.org/subjects/medicine.

An Unexpected Role of Neutrophils in Clearing Apoptotic Hepatocytes In Vivo

4-Apr-2023

The authors declare that no competing interests exist

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read more here:
White blood cells play unexpected role in clearing out dead liver cells - EurekAlert

Mendus presents an update on the use of its DCOne platform to source high-quality NK cell therapies at the 8th Annual Innate Killer Summit – Yahoo…

Mendus AB

DCONE-DRIVEN EXPANSION OF MEMORY NK CELLS BUILDS THE BASIS FOR NOVEL PROPRIETARY PIPELINE PROGRAM

Mendus AB (Mendus publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that it will present additional data highlighting the use of the companys proprietary DCOne platform for the ex vivo expansion of NK cells today at the 8th Annual Innate Killer Cell Summit in La Jolla, San Diego, CA.

Natural Killer (NK) cells are part of the innate immune system and form a first line of defense against infections and tumor cells. Memory NK cells are associated with improved tumor cell killing and significantly reduced relapse rates in bone marrow-transplanted leukemia patients. Memory NK cells therefore hold great therapeutic promise in the treatment of hematological cancers and potentially other tumor types.

Significant efforts in the NK field have been made to develop superior and reliable expansion methods for NK cells with optimal therapeutic efficacy, including efforts to improve memory phenotype. The NK cell research at Mendus has focused on using our proprietary DCOne platform to improve NK cell quality and specifically on memory NK cells, said Erik Manting, PhD, Chief Executive Officer of Mendus. The DCOne platform provides for an off-the-shelf source of cells which combine cancer cell and dendritic cell biology. Another important aspect of the DCOne cell line is that it is supported by an extensive regulatory dossier and has demonstrated an excellent safety profile in multiple clinical trials.

The data presented today and at SITC 2022 demonstrate that DCOne cells drive strong expansion of memory NK cells, which subsequently can be used in different therapeutic applications. The presence of activating ligands on the cell surface of DCOne-derived mature dendritic cells provide a mechanistic rationale for the observed expansion of memory NK cells with well-characterized molecular signatures.

Story continues

The Innate Killer Summit is an industry conference focused on improving patient care by advancing the understanding and enhancing of innate immune cell therapies. On March 30, 3.15pm PST (00:15 CET) Mendus CEO Erik Manting, PhD, will hold a presentation titled Developing Expansion Protocols to Enrich for Memory Phenotypes to Produce Quality over Quantity in Final NK Cell Therapy Products as part of the Clinical Scale Manufacturing track.

During the conference, Dr Manting also chaired a panel discussion titled Sharing a Vision of the Future for Commercial Scale Manufacturing of Innate Immune Cells on March 29.

FOR MORE INFORMATION, PLEASE CONTACT:

Erik MantingChief Executive OfficerE-mail: ir@mendus.com

INVESTOR RELATIONSCorey DavisLifeSci Advisors, LLCTelephone: + 1 212-915-2577E-mail: cdavis@lifesciadvisors.com

MEDIA RELATIONS

Mario BrkuljValency CommunicationsTelephone: +49 160 9352 9951E-mail: mbrkulj@valencycomms.eu

ABOUT MENDUS AB (PUBL)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/

Attachment

Link:
Mendus presents an update on the use of its DCOne platform to source high-quality NK cell therapies at the 8th Annual Innate Killer Summit - Yahoo...

RoslinCT and Lykan Bioscience announce that the MHRA has granted an MIA License for their cGMP Manufacturing facilities in Edinburgh, UK – Yahoo…

EDINBURGH, U.K. and HOPKINTON, Mass., March 30, 2023 /PRNewswire/ -- RoslinCT and Lykan Bioscience, leaders in ground-breaking Contract Development and Manufacturing for cell therapies, are delighted to announce that following a successful inspection at their Edinburgh, UK facility, from the Medicines and Healthcare products Regulatory Agency (MHRA), a Manufacturer's Authorisation Licence (MIA) for commercial manufacturing of cell therapy products has been granted.

RoslinCT_Lykan

Completed in late 2021, RoslinCT's newest 1,600 square-meter state-of-the-art facility,located in Edinburgh's BioQuarter, was designed to operate as a flexible and scalable manufacturing hub, housing five cGMP clean rooms and a dedicated training laboratory.The cGMP facility has been designed and purpose-built specifically to accommodate cell therapy manufacturing processes for both allogeneic and autologous therapies with or without genome editing requirements.

The license granted by the UK's regulatory body will allow RoslinCT and Lykan Bioscience, who are currently working with their partners to develop and manufacture cutting edge life-changing therapies and cures for patients suffering from some of the most debilitating medical conditions, to expand their service offering to produce market-approved cell therapy products.

Peter Coleman, Chief Executive Officer of RoslinCT said:"At RoslinCT we thrive on being pioneers in our sector, accelerating the delivery of these novel life-changing therapies to patients. The MIA commercial manufacturing licence is a huge landmark in the history of RoslinCT and is testament to the relationship we have developed with the MHRA and the hard work of our team. We will continue to work with our partners to deliver these life-saving therapies to patients".

Patrick Lucy, President & Chief Executive Officer of Lykan Bioscience, commented:"This license is a significant milestone for RoslinCT, Lykan Bioscience and our partners. Empowering our partners to progress efficiently from development to commercialization and deliver life-saving cell therapies to patients worldwide is at the core of our mission. The learnings acquired by RoslinCT that ultimately resulted in the receipt of the commercial manufacturing license will be invaluable as we align our global manufacturing operations".

Story continues

About RoslinCT

RoslinCT is a leading UK Cell Therapy Contract Development and Manufacturing Organisation (CDMO) focused on providing services for companies developing cell-based therapeutic products. Originally founded in 2006 as a spin-out from the Roslin Institute, RoslinCT expanded the broad range of scientific expertise available in the field of cell biology. Based at the Edinburgh BioQuarter, the company operates fully licensed GMP manufacturing facilities and has a proven track record in delivering cell-based products. For further information, please visit http://www.roslinct.com.

About Lykan Bioscience

Lykan Bioscience is an innovative contract development and manufacturing services organization (CDMO) focused on cell-based therapies. With decades of biopharmaceutical industry experience, Lykan offers a full range of development and manufacturing services. The state-of-the-art, purpose-built facility offering 14 independent manufacturing suites is uniquely designed to fully integrate cGMP principles and advanced software solutions to enable real-time testing, US/EU clinical and commercial manufacturing and release of product. Located in Hopkinton, Massachusetts, 25 miles southwest of downtown Boston and in the proximity of four international airports, Lykan Bioscience is ideally situated to deliver life-saving cell therapy treatments to patients on behalf of their partners. Visit http://www.lykanbio.com

For Media Enquiries

RoslinCT Marketing ManagerKaterina Tsita katerina.tsita@roslinct.com

Lykan Bioscience Senior Director of Marketing Carrie Zhang carrie.zhang@lykanbio.com

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/roslinct-and-lykan-bioscience-announce-that-the-mhra-has-granted-an-mia-license-for-their-cgmp-manufacturing-facilities-in-edinburgh-uk-301785134.html

SOURCE Lykan Bioscience

See the original post here:
RoslinCT and Lykan Bioscience announce that the MHRA has granted an MIA License for their cGMP Manufacturing facilities in Edinburgh, UK - Yahoo...

Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase … – InvestorsObserver

Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting

WESTLAKE VILLAGE, Calif., March 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today presented in a late-breaking clinical trial session at the American Academy of Dermatology (AAD) annual meeting (New Orleans, LA, March 17-21) new data from its INTEGUMENT-1 and INTEGUMENT-2 pivotal Phase 3 studies of roflumilast cream 0.15% in adults and children 6 years and older with mild to moderate atopic dermatitis (AD). Roflumilast cream is a once-daily, steroid-free topical formulation of a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor.

Both studies met the primary endpoint of IGA Success, defined as a validated Investigator Global Assessment Atopic Dermatitis (vIGA-AD) score of clear or almost clear plus a 2-grade improvement from baseline at Week 4 (INTEGUMENT-1: 32.0% roflumilast cream vs. 15.2% vehicle, P<0.0001; INTEGUMENT-2: 28.9% roflumilast cream vs. 12.0% vehicle, P<0.0001). In addition, rapid and significant improvements in v-IGA success were demonstrated as early as Week 2 (INTEGUMENT-1: 21.2% for roflumilast cream vs. 6.4% for vehicle; P<0.0001; INTEGUMENT-2: 17.7% for roflumilast cream vs 5.3% for vehicle; P< 0.0001).

Over 30% of individuals treated with roflumilast cream in each study achieved Worst Itch Numeric Scale (WI-NRS) Success at Week 4. In addition, a daily improvement in itch was observed in those treated with roflumilast cream with a significant improvement at 24 hours following the first application (P<0.05) as measured by WI-NRS.

Atopic dermatitis is a chronic skin disease common in both children and adults where pruritus, or itch, is the most reported and most burdensome symptom, and may cause substantially reduced quality of life and sleep disturbances, said Lawrence F. Eichenfield, MD, Chief of Pediatric and Adolescent Dermatology at Rady Children's Hospital-San Diego, Professor of Dermatology and Pediatrics and Vice-Chair of the Department of Dermatology at UC San Diego School of Medicine, and study investigator. Importantly, individuals treated with roflumilast cream experienced a significant and rapid improvement in the extent and severity of their atopic dermatitis, adding further to evidence of the potential of roflumilast cream as a treatment option for this disease. Additionally, these pivotal Phase 3 data show that roflumilast cream drove a significant and rapid reduction in itch as early as the first 24 hours, which could be a helpful early indication to children and adults that the treatment is working.

Roflumilast cream also demonstrated rapid and statistically significant improvements compared to vehicle on key secondary endpoints, with more than 40% of children age 6 and older and adults treated with roflumilast cream achieving a 75% reduction in Eczema Area and Severity Index (EASI-75) at Week 4 compared to vehicle (INTEGUMENT-1: 43.2% vs. 22.0%, P<0.0001; INTEGUMENT-2: 42.0% vs. 19.7%, P<0.0001). Additionally, significant improvements in EASI-75 were observed with roflumilast cream as early as Week 1 in both studies compared to vehicle (INTEGUMENT-1: 14.0% vs. 5.5%, p=0.0006; INTEGUMENT-2: 13.3% vs. 7.8%, p=0.0329). In both studies, approximately 40% of children and adults treated with roflumilast cream achieved a vIGA-AD score of Clear (0) or Almost Clear (1) at Week 4 (INTEGUMENT-1: 41.5% vs. 25.2%, P<0.0001; INTEGUMENT-2: 39% vs. 16.9%, P<0.0001).

Atopic dermatitis can have a huge impact on the quality of life for those affected, and also be challenging to treat, said Julie Block, President and CEO, National Eczema Association. Thankfully, our understanding of atopic dermatitis continues to grow, and the commitment from companies, such as Arcutis, to develop new treatment options aiming to provide people living with this disease a much-needed relief, is most welcome and appreciated.

We are pleased to present these data from our pivotal Phase 3 INTEGUMENT program, which demonstrated significant improvements in atopic dermatitis in children and adults across multiple efficacy endpoints, said Patrick Burnett MD, PhD, FAAD, Chief Medical Officer of Arcutis. Roflumilast cream was also shown to be safe and well-tolerated, critical considerations for the treatment of atopic dermatitis. We look forward to the continued development of roflumilast cream 0.15% for atopic dermatitis as we prepare to file a supplemental new drug application (sNDA) with the U.S. Food & Drug Administration (FDA) in the second half of this year.

Roflumilast cream 0.15% was well tolerated. The incidence of Treatment Emergent Adverse Events (TEAEs) was low in both active treatment and vehicle arms, with most TEAEs assessed as mild to moderate in severity, and no adverse event occurring in more than 3.5% of subjects in either arm. The most common TEAEs 2% in roflumilast-treated patients were headache (INTEGUMENT-1 2.3% vs 1.4%; INTEGUMENT-2 3.5% vs 0.9%), nausea (1.8% vs 0.9%; 2.0% vs 0%), and application site pain (2.1% vs. 0.5%; 0.9% vs. 0.9%). Local tolerability was favorable with more than 90% of those treated with roflumilast cream reporting no or mild sensation across arms in both trials at any timepoint.

About the INTEGUMENT Phase 3 Trials The INterventional Trial EvaluatinG roUMilast cream for the treatmENt of aTopic dermatitis (INTEGUMENT-1 and INTEGUMENT-2) are two identical Phase 3, parallel group, double blind, vehicle-controlled trials in which roumilast cream 0.15% or vehicle was applied once daily for four weeks to individuals 6 years of age and older with mild to moderate AD involving 3% body surface area. A total of 1,337 individuals were randomized across both studies. The primary endpoint was IGA Success, dened as vIGA-AD score of clear or almost clear plus a 2-grade improvement from baseline at Week 4. Multiple secondary endpoints were also evaluated, including itch as measured by WI-NRS as well as the proportion of subjects who attained an EASI-75 at Week 4.

After completing INTEGUMENT-1 and INTEGUMENT-2, individuals were eligible to enroll in an open-label extension study (INTEGUMENT-OLE) evaluating treatment with once-daily roflumilast cream 0.15% for up to 12 months.

Arcutis is enrolling a third pivotal Phase 3 trial, the INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis in PEDiatric patients (INTEGUMENT-PED) to evaluate roflumilast cream 0.05% in children 2 to 5 years of age with mild to moderate AD. The Company plans to report topline data from this study in the second half of 2023.

About Atopic Dermatitis AD is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United States. AD is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and inflammation. This reaction produces a red, itchy rash, most frequently occurring on the face, arms, and legs. The rash can cover significant areas of the body, in some cases half of the body or more. AD typically begins in early childhood and is chronic. It persists into adolescence and even adulthood in some individuals. The rash causes significant pruritus (itching), which can lead to skin damage caused by scratching or rubbing. Since a large percentage of AD patients are very young children, safety is a particularly important consideration in treatment selection.

About Roflumilast Cream Roflumilast cream is a next generation topical PDE4 inhibitor. PDE4 an established target in dermatology is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators. Roflumilast cream 0.3% (ZORYVE ) is approved by the FDA for the topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. Roflumilast cream for atopic dermatitis was evaluated at lower doses: 0.15% for adults and children 6 years of age and older and is being evaluated at 0.05% for children aged 2 to 5 years.

About ZORYVE ZORYVE (roflumilast) cream 0.3% is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION The use of ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

The most common adverse reactions (1%) include diarrhea (3%), headache (2%), insomnia (1%), nausea (1%), application site pain (1%), upper respiratory tract infection (1%), and urinary tract infection (1%).

Please see full Prescribing Information.

About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio that harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, seborrheic dermatitis, and alopecia areata. For more information, visit http://www.arcutis.com or follow Arcutis on LinkedIn , Facebook , and Twitter .

Forward-Looking Statements Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Companys current beliefs and expectations. Such forward-looking statements include, among others, statements regarding the potential for roumilast to be approved for the treatment of adults and children with AD, the potential to use roumilast cream over a long period of time, or chronically, the potential to use roumilast cream anywhere on the body, including the face and sensitive areas, timing for anticipated data of INTEGUMENT-PED, the potential sNDA ling and the potential for roumilast to advance the standard of care in AD and other inammatory dermatologic conditions. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 28, 2023, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts: Media Amanda Sheldon, Head of Corporate Communications asheldon@arcutis.com

Investors Eric McIntyre, Head of Investor Relations emcintyre@arcutis.com

Here is the original post:

Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase ... - InvestorsObserver

Top MEIDAM Dermatologists took Center Stage at AAD Conference discussing the 13 Billion Dollar Medical – EIN News

Dr. Saad Sami AlSogair presenting at AAD Global Education Day

MEIDAM at AAD Global Education Day

Middle East International Dermatology and Aesthetic Medicine

During the MEIDAM session, attendees gleaned information on subjects ranging from the business side of dermatology to mental health awareness. Topics included: * The origins and growth of dermatology * Evaluation of pruritus * Personality disorders in dermatological disorders * WhatsApp Dermatology * Alternatives to topical steroids

Dr. Khaled Al Nuaimi, President of MEIDAM, remarked, This was a great occasion where medical professionals gathered together from all around the world to share insights and breakthroughs in our field. MEIDAM is excited to be a part of this venture and to show our international colleagues the cutting-edge techniques developed by our members.

Global Newswire states that the 13.9 billion dollar medical aesthetics market is expected to triple in less than a decade. This innovative group of physicians is at the cusp of this wave. Dr. Saad Sami AlSogair, a preeminent speaker, conference facilitator, and renowned dermatologist, is at the helm of this growing organization. As the new general secretary of MEIDAM, the sought-after doctor and his esteemed colleagues offered the latest in dermatological advancement at the ADD conference.

In honor of the AAD Global Education Day, Dr. AlSogair presented his findings in Rheology of Hyaluronic Acid Dermal Fillers. His keynote speech addressed the effects of aging and the ongoing debate about surgery versus dermal fillers. Dr. AlSogair concluded that surgical interventions might make the apparent volume loss more evident. However, he encouraged using fillers because of their growing popularity amongst clients looking for a biodegradable and non-invasive approach. His well-attended talk led colleagues to rethink their stance and see the growth possibilities in this sector.

In response to the event, Dr. AlSogair says, This joint session began a beautiful partnership where MEIDAM and ADD can continue to increase awareness around our clienteles needs and the industrys growth. As the co-chair of this session, it was a privilege to share in this moment where medical professionals learned from one another, says AlSogair.

Newly elected AAD president, Dr. Seemal R. Desai, acknowledges the contributions of his 20,000-member group. As a leader in pigmented skin disorders, Dr. Desai understands the need to have many voices at the tables. The Texas-based doctor applauds the event saying, The addition of the MEIDAM session was a boost for our annual event. This group of internationally recognized physicians brought time-sensitive topics such as the correlation between mental health and dermatological issues and ideas around alternatives to steroids to the forefront.

For more information, contact Media Relations at mediarelations@aad.org.

AAD MediaMiddle East International Dermatology & Aesthetic Medicine +1 847-240-1714mediarelations@aad.org

MEIDAM at AAD Global Education Day

Middle East International Dermatology and Aesthetic Medicine

Read more:

Top MEIDAM Dermatologists took Center Stage at AAD Conference discussing the 13 Billion Dollar Medical - EIN News

Ousted WHO Official Takeshi Kasai Has Background in Emergency … – The Japan News

AP file photoTakeshi Kasai addresses the media in Manila on Oct. 7, 2019.

&The Yomiuri Shimbun

16:28 JST,March 9, 2023

Ousted World Health Organization official Takeshi Kasai is a doctor with a background in emergency medicine and an expert in infectious diseases and health crisis management.

Kasai has been dismissed from his post as director of the WHOs Western Pacific Regional Office over allegedly racist behavior, He joined the WHO after working at the then Health and Welfare Ministry.

He released a statement after allegations about racist and abusive misconduct emerged, saying that he never targeted employees of a particular nationality, although he acknowledged being hard on staff. Kasai also denied the accusation that he leaked confidential information.

Excerpt from:

Ousted WHO Official Takeshi Kasai Has Background in Emergency ... - The Japan News

ACP, Annals of Internal Medicine Host First Obesity Forum for … – American College of Physicians

Expert panel provides practical advice for managing overweight and obesity in clinical practice

PHILADELPHIA, March 14, 2023 On March 8, the American College of Physicians (ACP) andAnnals of Internal Medicinehosted the first virtual forum on the current clinical challenges related to managing overweight and obesity in clinical practice. During the forum, a panel of experts discussed three specific cases representing common clinical scenarios and answered audience questions about each of them. The panelists shared pragmatic clinical information and a replay of the full discussion is freely available to ACP members. The video and accompanying editorial from Christine Laine, MD, MPH, FACP, Senior Vice President of ACP and Editor-in-Chief of Annals of Internal Medicine and Christina Wee, MD, MPH, Senior Deputy Editor of Annals of Internal Medicine were published today in Annals of Internal Medicine.

Overweight and obesity now affects more than 40 percent of Americans and is associated with an increased risk for many common and serious illnesses, said Dr. Laine. Just as important, persons with obesity suffer from stigma, in large part because the condition has been erroneously viewed as a condition brought on by a persons own unhealthy behavior. In this forum, experts not only provide practical advice on management, but also help to dispel some of the misconceptions surrounding obesity that may contribute to unconscious bias among internal medicine physicians who are on the front lines treating these patients.

Dr. Wee, who is also an obesity researcher and Associate Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, served as moderator for the forum and introduced each of the panelists. These included:

After hearing the clinical vignettes, the panelists provided their recommendations for addressing the unique circumstances surrounding the patients overweight or obesity. The panelists made several important points, all of which are detailed in the forum editorial. Of note, they stressed that obesity is a complex medical condition resulting primarily from an interaction of genes and the environment. This distinction is crucial because physicians need to be able to discuss weight with patients without assigning blame or shame. It also goes a long way in explaining why modification of diet and exercise is difficult to achieve, notes Dr. Wee.

To solve a problem, one must be able to define it accurately. As such, the panelists discussed the importance of developing a better and more inclusive measure of overweight and obesity. Body mass index, or BMI, the current standard of body composition, is an imperfect measure that differs with ethnicity, sex, body frame, and muscle mass.

"In addition to better measures of obesity, we need better strategies for treatment," said Dr. Wee. "Studies show that diet and exercise alone are unlikely to result in long-term obesity benefit. The good news is that we now have effective pharmacological and surgical therapies that may need to be considered as part of a multi-component intervention for appropriate patients. Of course, shared decision-making is an important part of this approach."

The forum, Overweight and Obesity: Current Clinical Challenges, was the first forum of its kind hosted by ACP and Annals of Internal Medicine. Previous forums focused on the infectious diseases COVID-19 and MPox, and another forum focused on the physicians role in preventing firearm injury.

###

About the American College of PhysiciansTheAmerican College of Physiciansis the largest medical specialty organization in the United States with members in more than 145 countries worldwide. ACP membership includes 160,000 internal medicine physicians, related subspecialists, and medical students. Internal medicine physicians are specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment, and compassionate care of adults across the spectrum from health to complex illness. Follow ACP on Twitter,FacebookandInstagram.

About Annals of Internal MedicineAnnals of Internal Medicineis the flagship journal of the American College of Physicians (ACP).Annalsis the most widely read and cited general internal medicine journal and one of the most influential peer-reviewed clinical journals in the world.Annals mission is to promote excellence in medicine, enable physicians and other health care professionals to be well-informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. New content is published every Tuesday atAnnals.org. Follow Annals on TwitterandInstagram@AnnalsofIM and onFacebook.

ACP Media Contact:Andrew Hachadorian, (215) 351-2514,AHachadorian@acponline.orgAnnals Media Contact:Angela Collom, (215) 351-2653, ACollom@acponline.org

See more here:

ACP, Annals of Internal Medicine Host First Obesity Forum for ... - American College of Physicians

From ‘Grey’s Anatomy’ to ‘Abbott Elementary,’ pop culture is finally waking up to the climate crisis – Fast Company

From hurricanes bearing down on Florida to megafires burning in the West, the climate crisis seems to be everywhere, all at once. But on TV and film screens, mentions of climate are far rarer.

A study by the University of Southern Californias Media Impact lab examined more than 37,000 film and TV scripts that aired in the U.S. between 2016 and 2020. It found that only 2.8% even mentioned climate-adjacent words like solar panels, fracking, sea level rise, or renewable energy.

We know thats really low for a phenomenon that we are all experiencing, said Anna Jane Joyner, founder of Good Energy, a nonprofit consulting firm. The group has a goal: to get 50% of television and film scripts to touch on the climate crisis by 2027.

A growing number of shows are incorporating climate themes, Joyner said. Last season, the ABC hospital drama Greys Anatomy aired an episode called Hotter Than Hell, based on the real-life heat dome that baked the Pacific Northwest the previous summer. When the bodys exposed to rising temperatures, it has the ability to cool itself down. We sweat, our blood vessels dilate, and our heart rate increases, Meredith Grey, the shows titular character, narrated. But when the temperature starts to inch above 100 degrees, our bodies have to work overtime, leading to heat exhaustion. We become nauseated, dizzy, and confused.

The upcoming Apple TV+ anthology drama Extrapolations, starring Meryl Streep, Edward Norton and Marion Cotillard, is billed as an exploration of how the upcoming changes to our planet will affect love, faith, work and family on a personal and human scale.

Hulus Indigenous American teen comedy-drama Reservation Dogs features Dallas Goldtooth, an advocate with the Indigenous Environmental Network and includes references to the Land Back Indigenous sovereignty movement, which is part of a wider climate justice movement.

On ABCs Abbott Elementary, Principal Ava complains about a February hotter than the devils booty, to which a colleague replies: Climate change. We are living in the middle of its disastrous effects.

[The climate crisis] is such a part of our global and individual experience, and thats only going to become more so in the next decade, Joyner said. Eventually its going to be an intentional creative choice to not include mentions of climate change, and stories will feel outdated if they dont acknowledge this is part of our world now.

Research shows that people tend to underestimate how much others care about climate changethey think they care more than their neighbors or family members. While 70% of American adults say they are concerned or alarmed about the climate crisis, theyre not talking about itonly about one-third reported discussing the topic with their friends or family.

That creates a sense of isolation and anxiety, Joyner said. Television and film can do a lot to assuage that because it validates the audiences own experiences and feelings.

That means that climate storylines can be comedic, absurdist, or dramatic. In fact, Joyner said she finds doom and apocalypse plotlines to be limiting. People need more stories about the future we do want, she said.

Showing that climate change is something that is real, and happening now can galvanize audiences to act, said Max Boykoff, a researcher at the University of Colorado Boulder who studies climate change communication. Even in the last few years, weve been seeing this more and morenot just futuristic portrayals that are talking about climate change, but showing where we live and whats going on right now, he said. This isnt just about sacrifice. This can be about innovation, it can be about opportunity, it can be about actually having fun.

Victor Quinaz, a writer and producer on Netflixs Big Mouth and GLOW, said its not always easy to bring up the climate crisis in a pitch meeting. I dont think I would ever go into a room and pitch, this is about climate change, he said. That is such a pitch-killer. I think we have to be far more subtle about the storytelling.

On Big Mouth, Quinaz said his team consulted neuroscientists, psychiatrists, and other experts to understand what kids were feeling during pubertyand one predominant emotion was anxiety. Climate anxiety is a major stressor among young people and something Quinaz weaves into storylines: On one episode, Andrew Gloubermans family visits Florida, when a massive sinkhole opens up and devours the west coast of the state.

Quinaz is currently developing a show with Jenji Kohan (Weeds, Orange is the New Black) based on his experiences as a disaster relief volunteer. For me, the story wasnt about climate change, it was about how we help people in this time period, and the anxiety of living through this time, he said.

Dorothy Fortenberry, a writer and producer on Extrapolations, said she sees more interest in climate plotlines in Hollywood. Just in the last five years, Ive been a part of many more conversations about how to bring an awareness of the complexity of climate change to the show they already want to write, she said. People are asking: Wheres the climate part of that show?

Fortenberry points to short climate mentionsin Shen Wengs new Netflix standup special, the comedian leans into a joke about climate change and then moves on. It doesnt feel like pausing and doing a Very Special Episode, it doesnt feel like you leave the narrative world, she said. Its not like a 90s sitcom that suddenly needs to talk about bulimia for 26 seconds.

She hopes that climate stories will be ubiquitousbut also multifaceted. If all the climate stories are the same, and the same type of view, it will be boring and bad, said Fortenberry. My hope is every creative person takes this in the direction that is fruitful for the narrative and we end up with a real panoply of narratives.

View original post here:
From 'Grey's Anatomy' to 'Abbott Elementary,' pop culture is finally waking up to the climate crisis - Fast Company

Paris-based startup Gourmey uses the Big Idea Ventures accelerator program as a launch pad and goes on to raise the world’s largest cultivated meat…

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- French cultivated meat startup Gourmey, who was part of the Big Idea Ventures programs first cohort, has just raised an oversubscribed 48M Series A. This is the worlds largest Series A round for a cultivated meat startup.

Gourmey joined the Big Idea Ventures accelerator program in 2019. The global program facilitated the Paris-based startups move to Singapore, where it worked closely with a dedicated Big Idea Ventures team to lay the foundation for its success.

Andrew D. Ive, Founder and Managing General Partner at Big Idea Ventures, said: Gourmey has gone from strength to strength ever since joining our first cohort. Their agile team, bio-engineering achievements and focus on scalable solutions have allowed them to move faster than others and build the foundation for growth and commercialization. As one of their first investors, we will keep supporting Nicolas and the whole Gourmey team in this next step of their exciting journey.

Gourmey creates sustainable restaurant-grade meats directly from real animal cells, with an initial focus on premium meats and cultivated foie gras as their flagship product. Cultivated meat production consumes significantly less land and water and could cut the climate impact of meat production by up to 92%.

With this financing, the French startups will be opening a 46,000-square-foot commercial production facility and R&D center in Paris, France the largest cultivated meat hub in Europe to fast-track commercialization globally.

About Big Idea Venture (BIV)Big Idea Ventures is a venture firm focused on solving the world's greatest challenges by backing the world's best entrepreneurs, scientists and engineers. To date, BIV has invested in 100+ companies across 22 countries with a focus on protein alternatives and food tech. The investments were made through their New Protein Fund I (NPF I), which is backed by leading food corporations including AAK, Avril, Bel, Bhler, Givaudan, Meiji, Temasek Holdings, and Tyson Foods. New Protein Fund II will be available in Q4 2022 and will build on the successes of NPF I. For more information, visit https://bigideaventures.com

About GourmeyGourmeys mission is to accelerate the worlds transition toward more ethical, sustainable and healthy meat. The company creates sustainable restaurant-grade meats directly from real animal cells, thereby significantly reducing the impact on the environment. Founded in 2019 by CEO Nicolas Morin-Forest (ex-LOral), CTO Dr. Victor Sayous, PhD in molecular biology, and CSO Antoine Davydoff, cell biologist, the company is now a team of 40+ world-class scientists and engineers in the fields of gastronomic and food sciences, bioprocess engineering, and stem cell biology.

Media contact: [emailprotected] High-resolution images and logo of Gourmey: presskit.gourmey.com Find out more: gourmey.com

Read more:
Paris-based startup Gourmey uses the Big Idea Ventures accelerator program as a launch pad and goes on to raise the world's largest cultivated meat...

Hiltzik: The overhyping of AI – Los Angeles Times

The star of the show at Teslas annual AI Day (for artificial intelligence) on Sept. 30 was a humanoid robot introduced by Tesla Chief Executive Elon Musk as Optimus.

The robot could walk, if gingerly, and perform a few repetitive mechanical tasks such as waving its arms and wielding a watering can over plant boxes. The demo was greeted enthusiastically by the several hundred engineers in the audience, many of whom hoped to land a job with Tesla.

This means a future of abundance, Musk proclaimed from the stage. A future where there is no poverty. ... It really is a fundamental transformation of civilization as we know it.

We still dont have a learning paradigm that allows machines to learn how the world works, like human and many non-human babies do.

AI researcher Yann LeCun

Robotics experts watching remotely were less impressed. Not mind-blowing was the sober judgment of Christian Hubicki of Florida State University.

Some AI experts were even less charitable. The event was quite the dud, Ben Shneiderman of the University of Maryland told me. Among other shortcomings, Musk failed to articulate a coherent use case for the robot that is, what would it do?

Newsletter

Get the latest from Michael Hiltzik

Commentary on economics and more from a Pulitzer Prize winner.

Enter email address

Sign Me Up

You may occasionally receive promotional content from the Los Angeles Times.

To Shneiderman and others in the AI field, the Tesla demo embodied some of the worst qualities of AI hype; its reduction to humanoid characters, its exorbitant promises, its promotion by self-interested entrepreneurs and its suggestion that AI systems or devices can function autonomously, without human guidance, to achieve results that outmatch human capacities.

When news articles uncritically repeat PR statements, overuse images of robots, attribute agency to AI tools, or downplay their limitations, they mislead and misinform readers about the potential and limitations of AI, Sayash Kapoor and Arvind Narayanan wrote in a checklist of AI reporting pitfalls posted online the very day of the Tesla demo.

When we talk about AI, Kapoor says, we tend to say things like AI is doing X artificial intelligence is grading your homework, for instance. We dont talk about any other technology this way we dont say, the truck is driving on the road or a telescope is looking at a star. Its illuminating to think about why we consider AI to be different from other tools. In reality, its just another tool for doing a task.

That is not how AI is commonly portrayed in the media or, indeed, in announcements by researchers and firms engaged in the field. There, the systems are described as having learned to read, to grade papers or to diagnose diseases at least as well as, or even better than, humans.

Kapoor believes that the reason some researchers may try to hide the human ingenuity behind their AI systems is that its easier to attract investors and publicity with claims of AI breakthroughs in the same way that dot-com was a marketing draw around the year 2000 or crypto is today.

What is typically left out of much AI reporting is that the machines successes apply in only limited cases, or that the evidence of their accomplishments is dubious. Some years ago, the education world was rocked by a study purporting to show that machine- and human-generated grades of a selection of student essays were similar.

The claim was challenged by researchers who questioned its methodology and results, but not before headlines appeared in national newspapers such as: Essay-Grading Software Offers Professors a Break. One of the studys leading critics, Les Perelman of MIT, subsequently built a system he dubbed the Basic Automatic B.S. Essay Language Generator, or Babel, with which he demonstrated that machine grading couldnt tell the difference between gibberish and cogent writing.

The emperor has no clothes, Perelman told the Chronicle of Higher Education at the time. OK, maybe in 200 years the emperor will get clothes. ... But right now, the emperor doesnt.

A more recent claim was that AI systems may be as effective as medical specialists at diagnosing disease, as a CNN article asserted in 2019. The diagnostic system in question, according to the article, employed algorithms, big data, and computing power to emulate human intelligence.

Those are buzzwords that promoted the false impression that the system actually did emulate human intelligence, Kapoor observed. Nor did the article make clear that the AI systems purported success was seen in only a very narrow range of diseases.

AI hype is not only a hazard to laypersons understanding of the field but poses the danger of undermining the field itself. One key to human-machine interaction is trust, but if people begin to see a field having overpromised and underdelivered, the route to public acceptance will only grow longer.

Oversimplification of achievements in artificial intelligence evokes scenarios familiar from science fiction: futurescapes in which machines take over the world, reducing humans to enslaved drones or leaving them with nothing to do but laze around.

A persistent fear is that AI-powered automation, supposedly cheaper and more efficient than humans, will put millions of people out of work. This concern was triggered in part by a 2013 Oxford University paper estimating that future computerization placed 47% of U.S. employment at risk.

Shneiderman rejected this forecast in his book Human Centered AI, published in January. Automation eliminates certain jobs, as it has ... from at least the time when Gutenbergs printing presses put scribes out of work, he wrote. However, automation usually lowers costs and increases quality.... The expanded production, broader distribution channels, and novel products lead to increased employment.

Technological innovations may render older occupations obsolete, according to a 2020 MIT report on the future of work, but also bring new occupations to life, generate demands for new forms of expertise, and create opportunities for rewarding work.

A common feature of AI hype is the drawing of a straight line from an existing accomplishment to a limitless future in which all the problems in the way of further advancement are magically solved, and therefore success in reaching human-level AI is just around the corner.

Yet we still dont have a learning paradigm that allows machines to learn how the world works, like human and many non-human babies do, Yann LeCun, chief AI scientist at Meta Platforms (formerly Facebook) and a professor of computer science at NYU, observed recently on Facebook. The solution is not just around the corner. We have a number of obstacles to clear, and we dont know how.

So how can readers and consumers avoid getting duped by AI hype?

Beware of the sleight of hand that asks readers to believe that something that takes the form of a human artifact is equivalent to that artifact, counsels Emily Bender, a computational linguistics expert at the University of Washington. That includes claims that AI systems have written nonfiction, composed software or produced sophisticated legal documents.

The system may have replicated those forms, but it doesnt have access to the multitude of facts needed for nonfiction or the specifications that make a software program work or a document legally valid.

Among the 18 pitfalls in AI reporting cited by Kapoor and Narayanan are the anthropomorphizing of AI tools through images of humanoid robots (including, sadly, the illustration accompanying this article) and descriptions that utilize human-like intellectual qualities such as learning or seeing these tend to be simulations of human behavior, far from the real thing.

Readers should beware of phrases such as the magic of AI or references to superhuman qualities, which implies that an AI tool is doing something remarkable, they write. It hides how mundane the tasks are.

Shneiderman advises reporters and editors to take care to clarify human initiative and control. ... Instead of suggesting that computers take actions on their own initiative, clarify that humans program the computers to take these actions.

Its also important to be aware of the source of any exaggerated claims for AI. When an article only or primarily has quotes from company spokespeople or researchers who built an AI tool, Kapoor and Narayanan advise, it is likely to be over-optimistic about the potential benefits of the tool.

The best defense is healthy skepticism. Artificial intelligence has progressed over recent decades, but it is still in its infancy, and claims for its applications in the modern world, much less into the future, are inescapably incomplete.

To put it another way, no one knows where AI is heading. Its theoretically possible that, as Musk claimed, humanoid robots may eventually bring about a fundamental transformation of civilization as we know it. But no one really knows when or if that utopia will arrive. Until then, the road will be pockmarked by hype.

As Bender advised readers of an especially breathless article about a supposed AI advance: Resist the urge to be impressed.

Read more from the original source:
Hiltzik: The overhyping of AI - Los Angeles Times